Remnant Cholesterol—A Novel Risk Marker for Left Ventricular Remodeling and Dysfunction
Circulation: Cardiovascular Imaging
NOVEMBER 20, 2023
Circulation: Cardiovascular Imaging, Volume 16, Issue 11 , Page e016110, November 1, 2023.
Cardiovascular Imaging Cholesterol Circulation 
40 
Higher Noncalcified Plaque Volume Is Associated With Increased Plaque Vulnerability and Vascular Inflammation
Circulation: Cardiovascular Imaging
JANUARY 11, 2024
Circulation: Cardiovascular Imaging, Ahead of Print. P<0.001), and cholesterol crystal (42.0% BACKGROUND:Recently, it was reported that noncalcified plaque (NCP) volume was an independent predictor for cardiac events. versus 75.9%;P<0.001), P<0.001), thin-cap fibroatheroma (38.1% versus 20.7%;P<0.001),
Remnant Cholesterol in Young Adulthood Is Associated With Left Ventricular Remodeling and Dysfunction in Middle Age: The CARDIA Study
Circulation: Cardiovascular Imaging
NOVEMBER 20, 2023
Circulation: Cardiovascular Imaging, Volume 16, Issue 11 , Page e015589, November 1, 2023. BACKGROUND:Recent studies have shown that remnant cholesterol (RC) is associated with incident heart failure; however, its association with left ventricular (LV) structure and function is unclear.
Why Waiting Until Age 50 To Address Risk Factors For Heart Disease Is Too Late.
Dr. Paddy Barrett
FEBRUARY 27, 2024
‘Normal’ levels of risk factors such as blood pressure, cholesterol or blood glucose levels are often FAR from optimal. The Missing Variable Of Time One of the factors most often left out of cardiovascular risk discussions is the element of ‘cumulative time of exposure’ Risk is a function of two variables.
Trial Results: Low-Dose Colchicine HelpsTreat Cardiovascular Disease
DAIC
MARCH 31, 2025
Specifically, LODOCO reduces cardiac event risk in adult patients with established atherosclerotic cardiovascular disease by an additional 31% as compared to placebo. Prior research has shown that a 1% difference in PAV between treatment and placebo groups was associated with a 25% risk reduction in MACE.
Trial Results: Low-Dose Colchicine Helps Treat Cardiovascular Disease
DAIC
MARCH 31, 2025
Specifically, LODOCO reduces cardiac event risk in adult patients with established atherosclerotic cardiovascular disease by an additional 31% as compared to placebo. Prior research has shown that a 1% difference in PAV between treatment and placebo groups was associated with a 25% risk reduction in MACE.
Longitudinal Assessment of Subclinical Arterial Inflammation in Patients Receiving Immune Checkpoint Inhibitors by Sequential [18F]FDG PET Scans
Circulation: Cardiovascular Imaging
FEBRUARY 4, 2025
Circulation: Cardiovascular Imaging, Ahead of Print. Baseline arterial [18F]FDG uptake correlated with traditional cardiovascular risk factors, such as body mass index and male sex. Cross-sectional analyses suggested a negative effect of cholesterol-lowering medication on arterial [18F]FDG uptake at follow-up.
Let's personalize your content